Skip to main content
. 2019 Sep 3;33(1):131–136. doi: 10.1007/s10278-019-00271-7

Table 1.

Number of reports by modality and follow-up recommendation

US 2646
  Follow-up indicated (+) 249
  No follow-up indicated (−) 2397
  Prevalence 9.4%
CT 2557
  Follow-up indicated (+) 324
  No follow-up indicated (−) 2233
  Prevalence 12.7%
MR 797
  Follow-up indicated (+) 162
  No follow-up indicated (−) 635
  Prevalence 20.3%
All modalities 6000
  Follow-up indicated (+) 735
  No follow-up indicated (−) 5265
  Prevalence 12.3%